Desmopressin, Monosymptomatic Nocturnal Enuresis, Nocturnal Enuresis in Children
Conditions
Keywords
monosymptomatic nocturnal enuresis, nocturnal enuresis, desmopressin, Ginkgo Biloba
Brief summary
the efficacy of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis
Detailed description
Bedwetting among children is a common disorder, affecting 30% at age 4, 10% at age 6, 3% at age 12, and 1% at age. Untreated, the spontaneous cure rate is about 15% a year. Treatment is dominated by two approaches, enuresis alarm and drugs. Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin. For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%. However, numerous reports of side effects, some lethal, have led to a decline in its use. One of theory of nocturnal enuresis is deep sleep in children, this the main cornerstone in using Alarm as line of management. On the other hand drugs used in re-habitation of sleep rhythm seems to be with great benefits in management as GINKGO BILOBA. Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; anti-inflammation; anti-tumor activities; anti-aging, and improve night sleep rhythm. the aim of this study is to evaluate the effect of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis.
Interventions
DRUGGinkgo Biloba oral tablet
patients receive Ginkgo Biloba oral tablet 120 mg once daily
patient receives desmopressin 0.2 mg oral tablet once daily
DRUGGinkgo Biloba like Placebo
patients receive Ginkgo Biloba like Placebo oral tablet once daily
DRUGDesmopressin like Placebo
patients receive Desmopressin like Placebo oral tablet once daily
Sponsors
Menoufia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* all children with monosymptomatic nocturnal enuresis.
Exclusion criteria
* children with day and night wetting.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Night wetting frequency | 1, 3 months | Night wetting frequency is measured by the number of wet nights per week. |
Countries
Egypt
Outcome results
None listed